1
|
Trabolsi A, Arumov A, Yin J, Halmos B, Brodskiy P, Oberley MJ, Hoon DSB, Liu SV, Wei S, Kang I, Schatz JH. Pan-cancer association between increased iron utilization and poor prognosis highlights potential of transferrin receptor-targeting therapies in multiple tumor types. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.3120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3120 Background: The cell-surface transferrin receptor TFR1 imports iron-bound transferrin into cells via clathrin-mediated endocytosis. Tumors require constitutive iron import to drive proliferation, and several studies establish TFR1 as a target able to facilitate intracellular delivery of cytotoxic therapeutic molecules. Our own work previously revealed association between high expression of TFRC, the gene encoding TFR1, and high risk for poor outcome in diffuse large B-cell lymphoma (DLBCL). We showed therapetuic targeting of TFR1 in DLBCL results in significant anti-tumor benefit. Systematic analysis of TFRC expression as a prognostic marker across tumor types, however, has not been investigated. Methods: Tissue samples underwent comprehensive molecular profiling at Caris Life Sciences. Analyses included next generation sequencing of DNA (592 Gene Panel, NextSeq, or whole exome sequencing, NovaSeq), RNA (NovaSeq, whole transcriptome sequencing, WTS) and immunohistochemistry. Overall survival (OS) was calculated from date of tissue collection to last contact from insurance claims data and employed Kaplan-Meier analysis by Wilcoxon statistics, with p < 0.05 defined as significant. Results: Amongst 47 cancer types included, colorectal cancer (CRC) displayed the highest level of TFRC mRNA, followed by gastric cancer. In an all-tumor cohort (n = 93248), patients with higher TFRC expression (cutoff = median) had significantly worse OS (HR = 1.348, 95% CI [1.317-1.38], p < 0.00001). This was statistically significant in 23 individual tumor types. Drilling down further, TFRC adverse prognostic value was mainly driven by cohorts with larger number of samples in the database, including non-small cell lung cancer (n = 17309), CRC (n = 12860), breast cancer (n = 8632), ovarian carcinoma (n = 7998), uterine neoplasms (n = 6097), prostate adenocarcinoma (n = 3411), glioblastoma (n = 2821), gastric cancer (n = 1579), and others. Surprisingly, TFRC overexpression correlated with improved outcome in vulvar squamous cell carcinoma (VSCC, n = 297). TFRC was found to be most prognostic in prostate adenocarcinoma with median OS 1139 days in pts with high vs 3230 days in pts with low TFRC (HR = 2.556, 95% CI [2.213-2.951], p < 0.00001). Conclusions: Our study is the first to combine modern molecular profiling with a large cohort of clinical tissue samples to reveal a prognostic role for TFRC expression in a variety of solid tumor types. We found TFRC overexpression to be prognostic in a large proportion of histologies, though surprisingly association with improved OS in VSCC. Highest expression occured in CRC and gastric cancer, diseases with needs for new therapies. A number of TFR1-targeting therapeutics are currently at various stages of development, and warrant further investigation in disease cohorts identified from our study.
Collapse
Affiliation(s)
- Asaad Trabolsi
- University of Miami/Jackson Memorial Hospital, Miami, FL
| | - Artavazd Arumov
- University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
| | - Jun Yin
- Caris Life Sciences, Phoenix, AZ
| | - Balazs Halmos
- Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY
| | | | | | - Dave S. B. Hoon
- Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA
| | - Stephen V. Liu
- Georgetown University, Department of Hematology and Oncology, School of Medicine, Washington, DC
| | - Shuanzeng Wei
- Fox Chase Cancer Center, Department of Pathology, Philadelphia, PA
| | - Irene Kang
- Division of Oncology, USC Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, CA
| | | |
Collapse
|
2
|
Li L, Pongtornpipat P, Tiutan T, Kendrick SL, Park S, Persky DO, Rimsza LM, Puvvada SD, Schatz JH. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Leukemia 2015; 29:1702-12. [PMID: 25882699 PMCID: PMC4526343 DOI: 10.1038/leu.2015.99] [Citation(s) in RCA: 80] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2015] [Revised: 03/10/2015] [Accepted: 04/08/2015] [Indexed: 01/13/2023]
Abstract
Better treatments are needed for patients with diffuse large B-cell lymphoma (DLBCL) at high risk of failing standard therapy. Avoiding apoptosis is a hallmark of cancer, and in DLBCL the redundantly functioning anti-apoptotic proteins BCL2 and MCL1 are frequently expressed. Here, we explore drugs that cause loss of MCL1, particularly the potent new cyclin-dependent kinase inhibitor dinaciclib, which knocks down MCL1 by inhibiting CDK9. Dinaciclib induces apoptosis in DLBCL cells but is completely overcome by increased activity of BCL2. We find clinical samples have frequent co-expression of MCL1 and BCL2, suggesting therapeutic strategies targeting only one will lead to treatment failures due to activity of the other. The BH3 mimetic ABT-199 potently and specifically targets BCL2. Single-agent ABT-199 had modest anti-tumor activity against most DLBCL lines and resulted in compensatory up-regulation of MCL1 expression. ABT-199 synergized strongly, however, when combined with dinaciclib and with other drugs affecting MCL1, including standard DLBCL chemotherapy drugs. We show potent anti-tumor activities of these combinations in xenografts and in a genetically accurate murine model of MYC-BCL2 double-hit lymphoma. In sum, we reveal a rational treatment paradigm to strip DLBCL of its protection from apoptosis and improve outcomes for high-risk patients.
Collapse
Affiliation(s)
- L Li
- Bio5 Institute, University of Arizona Cancer Center, Tucson, AZ, USA
| | - P Pongtornpipat
- Bio5 Institute, University of Arizona Cancer Center, Tucson, AZ, USA
| | - T Tiutan
- College of Medicine, University of Arizona Cancer Center, Tucson, AZ, USA
| | - S L Kendrick
- Department of Pathology, University of Arizona Cancer Center, Tucson, AZ, USA
| | - S Park
- Department of Medicine, University of Arizona Cancer Center, Tucson, AZ, USA
| | - D O Persky
- Department of Medicine, University of Arizona Cancer Center, Tucson, AZ, USA
| | - L M Rimsza
- Department of Pathology, University of Arizona Cancer Center, Tucson, AZ, USA
| | - S D Puvvada
- Department of Medicine, University of Arizona Cancer Center, Tucson, AZ, USA
| | - J H Schatz
- 1] Bio5 Institute, University of Arizona Cancer Center, Tucson, AZ, USA [2] Department of Medicine, University of Arizona Cancer Center, Tucson, AZ, USA [3] Department of Pharmacology and Toxicology, University of Arizona Cancer Center, Tucson, AZ, USA
| |
Collapse
|
3
|
Li L, Pongtornpipat P, Park S, Schatz JH. Targeting MCL1 and BCL2 in diffuse large B-cell lymphoma. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e19509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Lingxiao Li
- Department of Hematology-Oncology, University of Arizona, Tucson, AZ
| | | | - Soyoung Park
- Department of Internal Medicine, University of Arizona, Tucson, AZ
| | | |
Collapse
|